Article metrics
PDF
Other content recommended for you
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
- Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
- Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
- Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
- Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
- Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
- Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
- PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
- Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells